EyeGate is a clinical-stage specialty pharmaceutical company developing and commercializing products for treating diseases and disorders of the eye. The Company has two proprietary platform technologies.

Our most advanced platform is based on cross-linked thiolated carboxymethyl hyaluronic acid (“CMHA-S”), a modified form of the natural polymer hyaluronic acid (“HA”), which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. The ability of CMHA-S to adhere longer to and protect the ocular surface, as well as resist degradation, makes it well-suited for treating various ocular surface injuries. Our lead CMHA-S product, EyeGate Ocular Bandage Gel (“OBG”) is being evaluated in a pilot study for corneal re-epithelialization following photorefractive keratectomy (“PRK”) surgery. EyeGate OBG is classified as a Class 2 medical device, and we plan to pursue U.S. regulatory clearance via the FDA’s De Novo 510(k) pathway.

Our second product, EGP-437, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate that is delivered into the ocular tissues via iontophoresis through a proprietary innovative drug delivery system, the EyeGate II Delivery System. EGP-437 is currently in late-stage clinical trials evaluating the product in treatment of both anterior uveitis and pain and inflammation following cataract surgery.